Reshape Lifesciences Stock Today
| RSLS Stock | USD 0.17 0.01 6.25% |
Performance0 of 100
| Odds Of DistressOver 81
|
ReShape Lifesciences is selling for under 0.17 as of the 25th of April 2024; that is 6.25 percent increase since the beginning of the trading day. The stock's lowest day price was 0.17. ReShape Lifesciences has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for ReShape Lifesciences are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of March 2024 and ending today, the 25th of April 2024. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 15th of November 2007 | Category Healthcare | Classification Health Care |
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California. The company has 23.46 M outstanding shares of which 729.32 K shares are at this time shorted by private and institutional investors with about 1.38 trading days to cover. More on ReShape Lifesciences
Moving against ReShape Stock
| 0.85 | HQY | HealthEquity Financial Report 3rd of June 2024 | PairCorr |
| 0.73 | THMO | Thermogenesis Holdings Financial Report 20th of May 2024 | PairCorr |
| 0.64 | RCM | R1 RCM Inc Earnings Call This Week | PairCorr |
| 0.64 | AGTI | Agiliti Financial Report 14th of May 2024 | PairCorr |
| 0.64 | VKTX | Viking Therapeutics Potential Growth | PairCorr |
| 0.56 | CERT | Certara Financial Report 13th of May 2024 | PairCorr |
| 0.51 | ELEV | Elevation Oncology Earnings Call This Week | PairCorr |
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
ReShape Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. ReShape Lifesciences' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding ReShape Lifesciences or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President CEO, Director | Barton Bandy | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering ReShape Lifesciences report their recommendations after researching ReShape Lifesciences' financial statements, talking to executives and customers, or listening in on ReShape Lifesciences' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering ReShape Lifesciences. The ReShape consensus assessment is calculated by taking the average forecast from all of the analysts covering ReShape Lifesciences. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to ReShape Lifesciences' liquidity, profitability, solvency, and operating efficiency, ReShape Lifesciences is not in a good financial situation at this time. It has a very high probability of going through financial hardship in May. Financial strength of ReShape Lifesciences is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ReShape Lifesciences' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to ReShape Lifesciences' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand ReShape Lifesciences' financial leverage. It provides some insight into what part of ReShape Lifesciences' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ReShape Lifesciences (RSLS) is traded on NASDAQ Exchange in USA. It is located in 1001 Calle Amanecer, San Clemente, CA, United States, 92673 and employs 29 people. ReShape Lifesciences is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 4 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate ReShape Lifesciences's market, we take the total number of its shares issued and multiply it by ReShape Lifesciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. ReShape Lifesciences conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 23.46 M outstanding shares of which 729.32 K shares are at this time shorted by private and institutional investors with about 1.38 trading days to cover.
ReShape Lifesciences currently holds about 11.49 M in cash with (16.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.51, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check ReShape Lifesciences Probability Of Bankruptcy
Ownership AllocationReShape Lifesciences owns a total of 23.46 Million outstanding shares. ReShape Lifesciences holds 11.16 pct. of its outstanding shares held by insiders and 1.96 pct. owned by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check ReShape Ownership Details
ReShape Stock Price Odds Analysis
Attributed to a normal probability distribution, the odds of ReShape Lifesciences jumping above the current price in 90 days from now is about 69.97%. The ReShape Lifesciences probability density function shows the probability of ReShape Lifesciences stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days ReShape Lifesciences has a beta of 0.8536 indicating ReShape Lifesciences market returns are related to returns on the market. As the market goes up or down, ReShape Lifesciences is expected to follow. Additionally, reShape Lifesciences has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of ReShape Lifesciences to move above the current price in 90 days from now is about 69.97 (This ReShape Lifesciences probability density function shows the probability of ReShape Stock to fall within a particular range of prices over 90 days) .
ReShape Stock Institutional Holders
Institutional Holdings refers to the ownership stake in ReShape Lifesciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of ReShape Lifesciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing ReShape Lifesciences' value.| Instituion | Recorded On | Shares | |
| Advisor Group Holdings, Inc. | 2023-12-31 | 5.0 | |
| Group One Trading, Lp | 2023-12-31 | 3.0 | |
| Ubs Group Ag | 2023-12-31 | 2.0 | |
| Baader Bank Inc | 2023-12-31 | 0.0 | |
| Renaissance Technologies Corp | 2023-12-31 | 0.0 | |
| Morgan Stanley - Brokerage Accounts | 2023-09-30 | 0.0 | |
| Cornerstone Planning Group Llc | 2023-12-31 | 0.0 | |
| Jpmorgan Chase & Co | 2023-09-30 | 0.0 | |
| Armistice Capital, Llc | 2023-12-31 | 0.0 | |
| Two Sigma Securities, Llc | 2023-12-31 | 75.6 K | |
| Virtu Financial Llc | 2023-12-31 | 73.5 K |
ReShape Lifesciences Historical Income Statement
ReShape Lifesciences Income Statement is one of the three primary financial statements used for reporting ReShape's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of ReShape Lifesciences revenue and expense. ReShape Lifesciences Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, ReShape Lifesciences' Other Operating Expenses is comparatively stable compared to the past year. Total Operating Expenses is likely to gain to about 24.6 M in 2024, whereas Operating Income is likely to drop (15.4 M) in 2024. View More FundamentalsReShape Stock Against Markets
Picking the right benchmark for ReShape Lifesciences stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in ReShape Lifesciences stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for ReShape Lifesciences is critical whether you are bullish or bearish towards ReShape Lifesciences at a given time. Please also check how ReShape Lifesciences' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in ReShape Lifesciences without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Stocks Directory Now
Stocks DirectoryFind actively traded stocks across global markets |
| All Next | Launch Module |
ReShape Lifesciences Corporate Directors
ReShape Lifesciences corporate directors refer to members of a ReShape Lifesciences board of directors. The board of directors generally takes responsibility for the ReShape Lifesciences' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of ReShape Lifesciences' board members must vote for the resolution. The ReShape Lifesciences board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Jon Tremmel | Independent Director | Profile | |
| Michael Mashaal | Director | Profile | |
| Gary Blackford | Director | Profile | |
| Lori McDougal | Director | Profile |
How to buy ReShape Stock?
Before investing in ReShape Lifesciences, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in ReShape Lifesciences. To buy ReShape Lifesciences stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of ReShape Lifesciences. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase ReShape Lifesciences stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located ReShape Lifesciences stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased ReShape Lifesciences stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as ReShape Lifesciences, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy ReShape Stock please use our How to Invest in ReShape Lifesciences guide.
Already Invested in ReShape Lifesciences?
The danger of trading ReShape Lifesciences is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of ReShape Lifesciences is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than ReShape Lifesciences. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile ReShape Lifesciences is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether ReShape Lifesciences is a strong investment it is important to analyze ReShape Lifesciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ReShape Lifesciences' future performance. For an informed investment choice regarding ReShape Stock, refer to the following important reports: Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ReShape Lifesciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy ReShape Stock please use our How to Invest in ReShape Lifesciences guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Complementary Tools for ReShape Stock analysis
When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |
Is ReShape Lifesciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ReShape Lifesciences. If investors know ReShape will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ReShape Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.91) | Revenue Per Share 1.457 | Quarterly Revenue Growth (0.36) | Return On Assets (0.84) | Return On Equity (2.21) |
The market value of ReShape Lifesciences is measured differently than its book value, which is the value of ReShape that is recorded on the company's balance sheet. Investors also form their own opinion of ReShape Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is ReShape Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ReShape Lifesciences' market value can be influenced by many factors that don't directly affect ReShape Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ReShape Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if ReShape Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ReShape Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.